Pulmonary Function Testing (PFT) is a pivotal tool in diagnosing and managing patients with respiratory diseases. However, interpreting the results can be complex and challenging. This article aims to provide a comprehensive guide to interpreting these tests.
Before diving into interpretation, it is crucial to understand the basics of PFT. The tests primarily measure lung volume, capacity, rates of flow, and gas exchange. These parameters provide insights into the functioning of the respiratory system and help identify any abnormalities.
Spirometry is the most common PFT, measuring the volume and speed of air that can be inhaled and exhaled. Key values include Forced Vital Capacity (FVC), Forced Expiratory Volume in 1 second (FEV1), and their ratio (FEV1/FVC). Obstructive diseases, such as COPD, present with reduced FEV1/FVC, while restrictive diseases, like pulmonary fibrosis, show reduced FVC with normal or increased FEV1/FVC.
Diffusing capacity of the lungs for carbon monoxide (DLCO) is a measure of gas exchange across the alveolar-capillary membrane. Reduced DLCO can indicate emphysema, pulmonary fibrosis, or pulmonary vascular diseases.
Residual Volume (RV), Total Lung Capacity (TLC), and Functional Residual Capacity (FRC) are measured using body plethysmography. Increased RV and FRC suggest air trapping, common in obstructive diseases, while decreased TLC indicates restrictive diseases.
Interpreting PFTs is an integral part of diagnosing and managing respiratory conditions. Understanding the nuances of the different parameters and their implications can greatly enhance clinical decision-making. Continuous learning and practice are vital to mastering this skill.
1.
Researchers use genomic technology to investigate aggressive skin cancer linked to burn scars
2.
The Growing Role of AI in Cancer Treatment
3.
Tafasitamab Regimen Improves PFS in Relapsed/Refractory Follicular Lymphoma
4.
Lower Prostate Cancer Mortality Linked to Unavailable Clinical Trials.
5.
Powerlifting through breast cancer: How a breast cancer survivor defied chemotherapy with strength training
1.
Drug Exposure in Tumor Microenvironments: Mechanisms, Clinical Implications, and Emerging Strategies
2.
Proteoform Networks in Blood Disorders: Mechanisms, Clinical Implications, and Emerging Therapeutic Strategies
3.
Antibody-Drug Conjugates and the Dawn of Targeted Cancer Therapy in 2025
4.
Revolutionizing Oncology Trials: Optimization, Matching, Diversity, and Decentralization
5.
Direct Oral Anticoagulants (DOACs) in Atrial Fibrillation: A Comprehensive Review
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion- Part II
2.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV
3.
Targeting Oncologic Drivers with Dacomitinib: A New Approach to Lung Cancer Treatment
4.
How Multidisciplinary Teams Support Modern Cancer Care
5.
Influence of CDK4/6 Inhibitors in Extending Progression-Free Survival (PFS) and Overall Survival in HR+/HER2- mBC Patients
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation